Is Roku Stock Undervalued Now?
At roughly $89 a share, Roku (NASDAQ: ROKU) trades for barely…
Buy
58
BLTE Quote, Financials, Valuation and Earnings
Last price:
$63.60
Seasonality move
:
33.78%
Day range:
$60.60 - $63.62
52-week range:
$43.70 - $86.53
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
13.02x
Volume:
180K
Avg. volume:
49.5K
1-year change:
29.15%
Market cap:
$2.1B
Revenue:
--
EPS (TTM):
-$1.36
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BLTE
Belite Bio
|
-- | -$0.42 | -- | -25.81% | $93.75 |
|
MRNA
Moderna
|
$116.3M | -$2.98 | -49.84% | -11.55% | $47.59 |
|
NBY
NovaBay Pharmaceuticals
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
NNVC
Nanoviricides
|
-- | -$0.20 | -- | -26.67% | -- |
|
OGEN
Oragenics
|
-- | -- | -- | -- | $1.00 |
|
TOVX
Theriva Biologics
|
-- | -$0.47 | -- | -95.63% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BLTE
Belite Bio
|
$63.22 | $93.75 | $2.1B | -- | $0.00 | 0% | -- |
|
MRNA
Moderna
|
$33.64 | $47.59 | $13B | -- | $0.00 | 0% | 4.17x |
|
NBY
NovaBay Pharmaceuticals
|
$0.69 | $0.85 | $4M | -- | $0.00 | 0% | 0.16x |
|
NNVC
Nanoviricides
|
$1.40 | -- | $22.4M | -- | $0.00 | 0% | -- |
|
OGEN
Oragenics
|
$1.42 | $1.00 | $1M | -- | $0.00 | 0% | 0.45x |
|
TOVX
Theriva Biologics
|
$0.50 | $7.00 | $4.1M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BLTE
Belite Bio
|
-- | -1.670 | -- | -- |
|
MRNA
Moderna
|
-- | -0.100 | -- | 3.92x |
|
NBY
NovaBay Pharmaceuticals
|
4.54% | -0.044 | 1.51% | 0.75x |
|
NNVC
Nanoviricides
|
-- | -0.318 | -- | -- |
|
OGEN
Oragenics
|
-- | 0.068 | -- | -- |
|
TOVX
Theriva Biologics
|
-- | -3.388 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BLTE
Belite Bio
|
-- | -$15.5M | -- | -- | -- | -- |
|
MRNA
Moderna
|
$17M | -$1.1B | -29.23% | -29.23% | -900% | -$1.2B |
|
NBY
NovaBay Pharmaceuticals
|
$1.6M | -$2.7M | -334.47% | -461.38% | -44% | -$1.3M |
|
NNVC
Nanoviricides
|
-- | -$2.2M | -- | -- | -- | -$2M |
|
OGEN
Oragenics
|
-- | -$2M | -- | -- | -- | -$2.1M |
|
TOVX
Theriva Biologics
|
-- | -$4.4M | -- | -- | -- | -$4.8M |
Belite Bio vs. Competitors
-
Which has Higher Returns BLTE or MRNA?
Moderna has a net margin of -- compared to Belite Bio's net margin of -907.48%. Belite Bio's return on equity of -- beat Moderna's return on equity of -29.23%.
Company Gross Margin Earnings Per Share Invested Capital BLTEBelite Bio-- -$0.45 -- MRNAModerna15.89% -$2.52 $10.1B -
What do Analysts Say About BLTE or MRNA?
Belite Bio has a consensus price target of $93.75, signalling upside risk potential of 48.29%. On the other hand Moderna has an analysts' consensus of $47.59 which suggests that it could grow by 41.47%. Given that Belite Bio has higher upside potential than Moderna, analysts believe Belite Bio is more attractive than Moderna.
Company Buy Ratings Hold Ratings Sell Ratings BLTEBelite Bio3 0 0 MRNAModerna4 17 1 -
Is BLTE or MRNA More Risky?
Belite Bio has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Moderna has a beta of 1.845, suggesting its more volatile than the S&P 500 by 84.505%.
-
Which is a Better Dividend Stock BLTE or MRNA?
Belite Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Belite Bio pays -- of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BLTE or MRNA?
Belite Bio quarterly revenues are --, which are smaller than Moderna quarterly revenues of $107M. Belite Bio's net income of -$14.3M is higher than Moderna's net income of -$971M. Notably, Belite Bio's price-to-earnings ratio is -- while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Belite Bio is -- versus 4.17x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BLTEBelite Bio-- -- -- -$14.3M MRNAModerna4.17x -- $107M -$971M
-
Which has Higher Returns BLTE or NBY?
NovaBay Pharmaceuticals has a net margin of -- compared to Belite Bio's net margin of -49.65%. Belite Bio's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.
Company Gross Margin Earnings Per Share Invested Capital BLTEBelite Bio-- -$0.45 -- NBYNovaBay Pharmaceuticals65.26% $1.42 $1.1M -
What do Analysts Say About BLTE or NBY?
Belite Bio has a consensus price target of $93.75, signalling upside risk potential of 48.29%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 22.83%. Given that Belite Bio has higher upside potential than NovaBay Pharmaceuticals, analysts believe Belite Bio is more attractive than NovaBay Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings BLTEBelite Bio3 0 0 NBYNovaBay Pharmaceuticals1 0 0 -
Is BLTE or NBY More Risky?
Belite Bio has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.443, suggesting its less volatile than the S&P 500 by 55.681%.
-
Which is a Better Dividend Stock BLTE or NBY?
Belite Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Belite Bio pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BLTE or NBY?
Belite Bio quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Belite Bio's net income of -$14.3M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Belite Bio's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Belite Bio is -- versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BLTEBelite Bio-- -- -- -$14.3M NBYNovaBay Pharmaceuticals0.16x -- $2.4M $7.7M
-
Which has Higher Returns BLTE or NNVC?
Nanoviricides has a net margin of -- compared to Belite Bio's net margin of --. Belite Bio's return on equity of -- beat Nanoviricides's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BLTEBelite Bio-- -$0.45 -- NNVCNanoviricides-- -$0.14 -- -
What do Analysts Say About BLTE or NNVC?
Belite Bio has a consensus price target of $93.75, signalling upside risk potential of 48.29%. On the other hand Nanoviricides has an analysts' consensus of -- which suggests that it could grow by 365.95%. Given that Nanoviricides has higher upside potential than Belite Bio, analysts believe Nanoviricides is more attractive than Belite Bio.
Company Buy Ratings Hold Ratings Sell Ratings BLTEBelite Bio3 0 0 NNVCNanoviricides0 0 0 -
Is BLTE or NNVC More Risky?
Belite Bio has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Nanoviricides has a beta of 0.882, suggesting its less volatile than the S&P 500 by 11.802%.
-
Which is a Better Dividend Stock BLTE or NNVC?
Belite Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nanoviricides offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Belite Bio pays -- of its earnings as a dividend. Nanoviricides pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BLTE or NNVC?
Belite Bio quarterly revenues are --, which are smaller than Nanoviricides quarterly revenues of --. Belite Bio's net income of -$14.3M is lower than Nanoviricides's net income of -$2.2M. Notably, Belite Bio's price-to-earnings ratio is -- while Nanoviricides's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Belite Bio is -- versus -- for Nanoviricides. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BLTEBelite Bio-- -- -- -$14.3M NNVCNanoviricides-- -- -- -$2.2M
-
Which has Higher Returns BLTE or OGEN?
Oragenics has a net margin of -- compared to Belite Bio's net margin of --. Belite Bio's return on equity of -- beat Oragenics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BLTEBelite Bio-- -$0.45 -- OGENOragenics-- -$3.60 -- -
What do Analysts Say About BLTE or OGEN?
Belite Bio has a consensus price target of $93.75, signalling upside risk potential of 48.29%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 2012.89%. Given that Oragenics has higher upside potential than Belite Bio, analysts believe Oragenics is more attractive than Belite Bio.
Company Buy Ratings Hold Ratings Sell Ratings BLTEBelite Bio3 0 0 OGENOragenics0 1 0 -
Is BLTE or OGEN More Risky?
Belite Bio has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Oragenics has a beta of 0.946, suggesting its less volatile than the S&P 500 by 5.446%.
-
Which is a Better Dividend Stock BLTE or OGEN?
Belite Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Belite Bio pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BLTE or OGEN?
Belite Bio quarterly revenues are --, which are smaller than Oragenics quarterly revenues of --. Belite Bio's net income of -$14.3M is lower than Oragenics's net income of -$2.2M. Notably, Belite Bio's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Belite Bio is -- versus 0.45x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BLTEBelite Bio-- -- -- -$14.3M OGENOragenics0.45x -- -- -$2.2M
-
Which has Higher Returns BLTE or TOVX?
Theriva Biologics has a net margin of -- compared to Belite Bio's net margin of --. Belite Bio's return on equity of -- beat Theriva Biologics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BLTEBelite Bio-- -$0.45 -- TOVXTheriva Biologics-- -$1.55 -- -
What do Analysts Say About BLTE or TOVX?
Belite Bio has a consensus price target of $93.75, signalling upside risk potential of 48.29%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1294.42%. Given that Theriva Biologics has higher upside potential than Belite Bio, analysts believe Theriva Biologics is more attractive than Belite Bio.
Company Buy Ratings Hold Ratings Sell Ratings BLTEBelite Bio3 0 0 TOVXTheriva Biologics1 1 0 -
Is BLTE or TOVX More Risky?
Belite Bio has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 0.816, suggesting its less volatile than the S&P 500 by 18.373%.
-
Which is a Better Dividend Stock BLTE or TOVX?
Belite Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Belite Bio pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BLTE or TOVX?
Belite Bio quarterly revenues are --, which are smaller than Theriva Biologics quarterly revenues of --. Belite Bio's net income of -$14.3M is lower than Theriva Biologics's net income of -$4.3M. Notably, Belite Bio's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Belite Bio is -- versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BLTEBelite Bio-- -- -- -$14.3M TOVXTheriva Biologics0.33x -- -- -$4.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Microsoft Be a $5 Trillion Stock?
Microsoft’s market capitalization sits near $3.73 trillion today. To clear the…
Where Will C3.ai Stock Be in 1 Year?
C3 .ai (NYSE: AI) has been the poster child for “hype versus execution.”…
Stock Ideas
Buy
69
Is NVDA Stock a Buy?
Market Cap: $4T
P/E Ratio: 56x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 43x
Sell
45
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Alerts
Buy
58
INKT alert for Jul 14
MiNK Therapeutics [INKT] is down 37.67% over the past day.
Buy
51
NEGG alert for Jul 14
Newegg Commerce [NEGG] is down 24.47% over the past day.
Buy
68
ATRO alert for Jul 14
Astronics [ATRO] is down 2.05% over the past day.
